



## **SENSIMED to open first distribution channel in Asia**



**Lausanne, November 9<sup>th</sup> 2010**, the company SENSIMED has developed the SENSIMED Triggerfish<sup>®</sup>, a revolutionary contact lens for monitoring continuously the fluctuations in intraocular pressure to facilitate the management of related diseases such as glaucoma.

Glaucoma is an asymptomatic, progressive and irreversible disease which leads to blindness unless adequate treatment is provided. Glaucoma is the second most common cause of blindness worldwide and affects about 68 million people. Abnormal intraocular pressure is one of known causes of glaucoma. This behavior is individual, has transient peaks and varies significantly over a 24 hour period. By providing ophthalmologists with the 24-hour profile of intraocular pressure, the SENSIMED Triggerfish<sup>®</sup> helps the doctor to better understand the condition of the patient, to provide personalized treatment, and to monitor the efficacy of the treatment over time.

Handok Pharmaceutical recently participated in a round of financing of SENSIMED and secured the exclusive distribution in Korea. Handok will also support SENSIMED with clinical trials and regulatory processes in this country. The potential market in Asia is important and represents about 50 million people affected by glaucoma. "We already received a large interest from Asian ophthalmologist and this partnership with Handok is a strong asset for the development of the company in Asia." Says Jean-Marc Wismer, CEO of SENSIMED.

Young Jin Kim, Chairman and Chief Executive Officer of Handok added, "Ophthalmology is one of the areas where we are trying to expand as a strategic area. We look forward to collaborating with Sensimed in clinical trials and market development for Sensimed Triggerfish in South Korea. "

### About SENSIMED:

Established in 2003, SENSIMED AG is a Swiss company with its principal focus on design, development and commercialization of integrated micro-systems for medical devices. SENSIMED was spun off from the well renowned Swiss Federal Institute of Technology (EPFL) and grows within a world-leading cluster for medical devices in the lake of Geneva area. SENSIMED has developed a new, patented, non-invasive product that will significantly improve identification and treatment of glaucoma disease by monitoring intraocular pressure around the clock. For more information, visit [www.sensimed.ch](http://www.sensimed.ch)

### About Handok Pharmaceutical:

HANDOK Pharmaceuticals Co., Ltd., (002390 KS), based in Seoul Korea, is a company posting 293B KRW in pharmaceutical, diagnostic, OTC sales and others in 2009. HANDOK is among ten domestic companies in Korea and it has never recorded a deficit year since its establishment. Handok, founded in 1954, is the pharmaceutical company in Korea with the most successful track records in various types of partnerships. It formed a JV with Hoechst in 1964, which led to the current strategic partnership with sanofi-aventis in Korea and, moreover, have 25 other partners focusing on innovative products, including CSL, Solvay, Actelion, Aeterna Zentaris among others. The company is also known to have leading expertise in various therapeutic categories including CV, Urology and respiratory system as well as to strive to get into oncology, CNS and ophthalmology area in the future. Handok maintains a world class GMP manufacturing facility and was the first local Korean company to incorporate clinical research capabilities with medical directors on staff. For more information, visit the HANDOK website at [www.handok.co.kr](http://www.handok.co.kr).

SENSIMED AG

Route de Chavannes 37 • 1007 Lausanne • Switzerland

Tel. +41 21 621 9191 • Fax. +41 21 621 9193

[www.sensimed.ch](http://www.sensimed.ch) • [info@sensimed.ch](mailto:info@sensimed.ch)